{"id":"cebranopadol-600-g","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2364605","moleculeType":"Small molecule","molecularWeight":"378.49"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cebranopadol's dual action on kappa and mu opioid receptors contributes to its analgesic effects. This mechanism allows for a more balanced approach to pain management, potentially reducing the risk of opioid-related side effects.","oneSentence":"Cebranopadol is a kappa opioid receptor agonist and mu opioid receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:15.843Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain"}]},"trialDetails":[{"nctId":"NCT05491785","phase":"PHASE1","title":"Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2022-07-29","conditions":"Pain","enrollment":30},{"nctId":"NCT05256108","phase":"PHASE1","title":"Assessment of Abuse Potential of Cebranopadol in Humans","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2022-03-28","conditions":"Human Abuse Potential","enrollment":38},{"nctId":"NCT01964378","phase":"PHASE3","title":"CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer","status":"TERMINATED","sponsor":"Tris Pharma, Inc.","startDate":"2013-10-29","conditions":"Pain, Neoplasms, Chronic Pain","enrollment":200},{"nctId":"NCT02031432","phase":"PHASE3","title":"CORAL XT - Open-label Extension Trial of the CORAL Trial","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2013-12-18","conditions":"Pain, Neoplasms, Chronic Pain","enrollment":76},{"nctId":"NCT01939366","phase":"PHASE2","title":"Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2013-09-27","conditions":"Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus","enrollment":699}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Treatment Phase","Experimental"],"phase":"phase_2","status":"active","brandName":"Cebranopadol 600 µg","genericName":"Cebranopadol 600 µg","companyName":"Tris Pharma, Inc.","companyId":"tris-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cebranopadol is a kappa opioid receptor agonist and mu opioid receptor agonist. Used for Chronic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}